SLNO · Categories · Conferences
SLNO - Conference and earnings call announcements
Soleno Therapeutics Inc. (SLNO) conference and earnings call announcements - real-time wire coverage filtered to Conferences only.
Recent Conferences for SLNO
- Soleno Therapeutics to Participate in Upcoming ConferencesREDWOOD CITY, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will participate in the following investor conferences in February and March: Guggenheim Emerging Outlook: Biotech Summit 2026Presentation Date: Thursday, February 12, 2026 at 11:30 AM ETPresentation Format: Fireside ChatWebcast: Here Oppenheimer 36th Annual Healthcare Life Sciences ConferencePresentation Date: Thursday, February 26, 2026 at 10:00 AM ETPresentation Format: Company presentation TD Cowen 46th Annual Health Care Conference Presentation Date: Wednesday
- Soleno Therapeutics to Present at the Piper Sandler 37th Annual Healthcare ConferenceREDWOOD CITY, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 37th Healthcare Conference on Thursday, December 4, 2025, at 9:00 AM Eastern Time. A live audio webcast and replay of the presentation will be available in the Investors section on the Company's website at www.soleno.life. About Soleno Therapeutics, Inc.Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare disease
- Soleno Therapeutics to Participate in Upcoming November ConferencesREDWOOD CITY, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will participate in the following investor conferences in November: Guggenheim Securities Healthcare Innovation ConferencePresentation Date: Tuesday, November 11, 2025 at 9:00 AM ETPresentation Format: Fireside ChatWebcast: Here Stifel 2025 Healthcare ConferencePresentation Date: Wednesday, November 12, 2025 at 8:40 AM ETPresentation Format: Fireside ChatWebcast: Here Jefferies London Healthcare ConferencePresentation Date: Tuesday, November 18, 2025 at 5:00 PM GMT
- Soleno Therapeutics to Participate in Upcoming September ConferencesREDWOOD CITY, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will participate in the following investor conferences in September: Cantor Global Healthcare ConferencePresentation Date: Wednesday, September 3, 2025 at 1:00 PM ETPresentation Format: Fireside ChatWebcast: Here Wells Fargo Healthcare ConferencePresentation Date: Thursday, September 4, 2025 at 1:30 PM ETPresentation Format: Fireside ChatWebcast: Here H.C. Wainwright 27th Annual Global Investment ConferencePresentation Date: Monday, September 8, 2025 at 4:00 PM ETP
- Soleno Therapeutics to Participate in Upcoming June ConferencesREDWOOD CITY, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will participate in the following investor conferences in June: Jefferies Global Healthcare ConferencePresentation Date: Wednesday, June 4, 2025 at 10:30 AM ETPresentation Format: Corporate PresentationWebcast: Here Goldman Sachs 46th Healthcare ConferencePresentation Date: Tuesday, June 10, 2025 at 8:40 AM ETPresentation Format: Corporate PresentationWebcast: Here A replay of both events will be available in the Investors section on the Company's website at www.sol
- Soleno Therapeutics to Participate in Upcoming February Investor ConferencesREDWOOD CITY, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will participate in the following investor conferences in February: Guggenheim SMID Cap Biotech ConferencePresentation Date: Thursday, February 6, 2025 at 2:00 PM ETPresentation Format: Fireside ChatWebcast: https://wsw.com/webcast/guggen2/slno/2028708 Oppenheimer 35th Annual Healthcare Life Sciences ConferencePresentation Date: Tuesday, February 11, 2025 at 2:40 PM ETPresentation Format: Corporate PresentationWebcast: https://wsw.com/webcast/oppenhei
- Soleno Therapeutics to Participate in Piper Sandler 36th Annual Healthcare ConferenceREDWOOD CITY, Calif., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that management will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Thursday, December 5, 2024, at 9:00 AM Eastern Time. A live audio webcast and replay of the fireside chat will be available in the Investors section on the Company's website at www.soleno.life. About Soleno Therapeutics, Inc.Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. An NDA for
- Soleno Therapeutics to Participate in Upcoming November Investor ConferencesREDWOOD CITY, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that management will participate in the following upcoming investor conferences: Event: Guggenheim Healthcare Innovation Conference Date: Monday, November 11, 2024Time: 10:00 AM ET Event: Stifel 2024 Healthcare Conference Date: Monday, November 18, 2024 Time: 4:45 PM ET Event: Jefferies London Healthcare ConferenceDate: Wednesday, November 20, 2024Time: 8:00 AM GT A live audio webcast and replay of the Guggenheim and Jefferies events will be availab
- Soleno Therapeutics to Present at 2024 Cantor Global Healthcare ConferenceREDWOOD CITY, Calif., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that management will present at the 2024 Cantor Global Healthcare Conference on Tuesday, September 17, 2024, at 8:00 AM Eastern Time. A live audio webcast and replay of the presentation will be available in the Investors section on the Company's website at www.soleno.life. About Soleno Therapeutics, Inc.Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. An NDA for its lead candidate, DCCR (dia
- Soleno Therapeutics to Participate in Upcoming Investor ConferencesREDWOOD CITY, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will participate in the following upcoming investor conferences: Event: Jefferies Global Healthcare ConferenceDay: Wednesday, June 5, 2024Time:11:30 AM Eastern Time Event:Goldman Sachs 45th Annual Global Healthcare ConferenceDay:Tuesday, June 11, 2024Time:4:00 PM ET A live audio webcast and replay of the events will be available in the Investors section on the Company's website at www.soleno.life. About So
- Soleno Therapeutics to Present at the TD Cowen 44th Annual Health Care ConferenceREDWOOD CITY, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will present at the TD Cowen 44th Annual Healthcare Conference on Monday, March 4, 2024, at 1:30 PM Eastern Time. A live audio webcast and replay of the presentation will be available in the Investors section on the Company's website at www.soleno.life. About Soleno Therapeutics, Inc.Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The comp
- Soleno Therapeutics to Present at Upcoming February Investor ConferencesREDWOOD CITY, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will present at the following upcoming investor conferences: Guggenheim Healthcare Talks | 6th Annual Biotechnology ConferenceThursday, February 8, 2024, at 2:30 PM Eastern Time 34th Annual Oppenheimer Healthcare Life Sciences ConferenceWednesday, February 14, 2024, at 11:20 AM Eastern Time Anish Bhatnagar, M.D., Chief Executive Officer, will also be participating in a fireside chat, hosted by Dr. Lela
- Soleno Therapeutics to Participate in the Guggenheim Healthcare Talks Genomic Medicines and Rare Disease DaysREDWOOD CITY, Calif., March 28, 2023 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will participate in a fireside chat at the Guggenheim Healthcare Talks Genomic Medicines and Rare Disease Days on Monday, April 3, 2023 at 10:10 AM Eastern Time. A live audio webcast and replay of the fireside chat will be available in the Investors section on the Company's website at www.soleno.life. About Soleno Therapeutics, Inc.Soleno is focused on the development and commercialization of novel therape
- Soleno Therapeutics to Participate in the Oppenheimer 33rd Annual Healthcare ConferenceREDWOOD CITY, Calif., March 07, 2023 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will participate in a fireside chat at Oppenheimer's 33rd Annual Healthcare Conference on Tuesday, March 14, 2023 at 11:20 AM Eastern Time. A live audio webcast and replay of the fireside chat will be available in the Investors section on the Company's website at www.soleno.life. About Soleno Therapeutics, Inc.Soleno is focused on the development and commercialization of novel therapeutics for the treatmen
- Soleno Therapeutics Announces Initiation of Randomized Withdrawal Study of DCCR for the Treatment of Prader-Willi SyndromeREDWOOD CITY, Calif., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno or the Company) (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it has initiated a randomized withdrawal period of Study C602, an ongoing open-label extension study of DCCR (Diazoxide Choline) Extended-Release tablets for the treatment of Prader-Willi syndrome (PWS). "Initiation of the randomized withdrawal period of Study C602 represents a significant milestone for our late-stage DCCR development program," said Anish Bhatnagar, M.D., Chief Executive Officer of Soleno. "As we announced previously, follow
- Soleno Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment ConferenceREDWOOD CITY, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 24th Global Investment Conference, being held September 12-14, 2022, virtually and in-person at the Lotte New York Palace Hotel in New York, NY. The presentation will be available on-demand for registered participants through the H.C. Wainwright conference portal starting at 7:00 a.m. Eastern Time on Monday, September 12, 2022, and a copy of the infor
- Soleno Therapeutics to Participate in the H.C. Wainwright Global Investment ConferenceREDWOOD CITY, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will present a corporate overview at the H.C. Wainwright Global Investment Conference, being held May 23-26, 2022, virtually and in Miami, FL. The presentation will be available on-demand beginning at 7 AM Eastern Time on Tuesday, May 24, 2022 in the Investors section on the Company's website at www.soleno.life. About Soleno Therapeutics, Inc.Soleno is focused on the development and commercialization of nove
- Soleno Therapeutics to Participate in the BIO CEO & Investor ConferenceREDWOOD CITY, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will present a corporate overview at the BIO CEO & Investor Conference on Tuesday, February 15, 2022 at 2:15 PM Eastern Time. About Soleno Therapeutics, Inc.Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company's lead candidate, DCCR extended-release tablets, a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS),
- Soleno Therapeutics to Participate in the LifeSci Partners 11th Annual Corporate Access EventREDWOOD CITY, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will participate in a panel discussion during the LifeSci Partners 11th Annual Corporate Access Event. Details for the panel discussions are below: Title:Patient Advocacy: Honing the Skill for Crossover Communications between Patients and StakeholdersDate:Thursday, January 6, 2022Time:2:00 PM ETWebcast:https://wsw.com/webcast/lifesci3/panel10/2456850 A live audio webcast and replay of the panel discussio
- Soleno Therapeutics to Participate in the 2021 Cantor Virtual Global Healthcare ConferenceREDWOOD CITY, Calif., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will participate in a fireside chat at the 2021 Cantor Virtual Global Healthcare Conference on Thursday, September 30, 2021 at 2:40 PM Eastern Time. A live audio webcast and replay of the presentation will be available in the Investors section on the Company's website at www.soleno.life. About Soleno Therapeutics, Inc.Soleno is focused on the development and commercialization of novel therapeutics for the
- Soleno Therapeutics to Participate in the Oppenheimer Fall Healthcare Life Sciences and MedTech SummitREDWOOD CITY, Calif., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will present a corporate overview at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit on Monday, September 20, 2021 at 1:15 PM Eastern Time. A live audio webcast and replay of the presentation will be available in the Investors section on the Company's website at www.soleno.life. About Soleno Therapeutics, Inc.Soleno is focused on the development and commercialization of novel therapeutics
- Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2021 Financial ResultsREDWOOD CITY, Calif., July 28, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update, and reported financial results for the three and six months ended June 30, 2021. "The Soleno team remains focused on achieving regulatory approval for DCCR for the treatment of Prader-Willi syndrome, or PWS," said Anish Bhatnagar, M.D., Chief Executive Officer of Soleno Therapeutics. "We are continuing our dialogue with the U.S. Food and Drug Administration (FDA) and, as recently announced, intend to submit the clinical study reports from DE
- Soleno Therapeutics to Host Webinar Highlighting DCCR for Treatment of Prader-Willi Syndrome at European Congress on Endocrinology 2021REDWOOD CITY, Calif., May 21, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that the Company will host a webinar highlighting DCCR (diazoxide choline) Extended-Release tablets for the treatment of Prader-Willi syndrome (PWS) at the 23rd European Congress of Endocrinology 2021, on Monday, May 24, 2021, at 8:15 AM Central European Summer Time (CEST). The webinar, titled "Results from DESTINY PWS, a Randomized Double-Blind Placebo-Controlled Phase 3 Study in Subjects with Prader-Willi Syndrome," will feature presentations by PWS key opini
- Soleno Therapeutics to Participate in the Oppenheimer Rare & Orphan Disease SummitREDWOOD CITY, Calif., May 20, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will present a corporate overview at the Oppenheimer Rare & Orphan Disease Summit on Friday, May 21, 2021 at 1:15 PM Eastern Time. A live audio webcast and replay of the presentation will be available in the Investors section on the Company's website at www.soleno.life. About Soleno Therapeutics, Inc.Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare di
- Soleno to Participate in the 31st Annual Oppenheimer Healthcare ConferenceREDWOOD CITY, Calif., March 09, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will participate in a fireside chat at the 31st Annual Oppenheimer Healthcare Conference on Tuesday, March 16, 2021 at 1:50 PM Eastern Time. A live audio webcast and replay of the fireside chat will be available in the Investors section on the Company’s website at www.soleno.life. About Soleno Therapeutics, Inc.Soleno is focused on the development and commercialization of novel therapeutics for the treatm
- Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2020 Financial ResultsREDWOOD CITY, Calif., March 03, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update and announced financial results for the fourth quarter and year ended December 31, 2020. Fourth Quarter 2020 and Recent Corporate Highlights Announced analysis of Phase 3 DESTINY PWS (C601) study evaluating once-daily Diazoxide Choline Controlled-Release (DCCR) tablets for patients with Prader Willi Syndrome (PWS), limited to data collected through March 1, 2020, before the onset of the COVID-19 pandemic Primary endpoint demonstrated a sta
- Soleno Therapeutics Provides Recap of Key Opinion Leader Webinar on DCCR for Treatment of Prader-Willi SyndromeREDWOOD CITY, Calif., Feb. 05, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today hosted a Key Opinion Leader (KOL) webinar and provided an update on the Company’s ongoing Phase 3 program evaluating once-daily Diazoxide Choline Controlled Release (DCCR) tablets for the treatment of Prader-Willi Syndrome (PWS). “PWS is estimated to impact about 10,000 – 20,000 people in the U.S., and is characterized by hyperphagia, an insatiable feeling of hunger, and various other behavioral and metabolic abnormalities that severely impact the daily lives of pa
- Soleno Therapeutics to Host Key Opinion Leader Meeting on DCCR for the Treatment of Prader-Willi SyndromeREDWOOD CITY, Calif., Jan. 28, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced it will host a Key Opinion Leader (KOL) webinar and provide a corporate update on Thursday, February 4, 2021, at 12:00 PM Eastern Time, featuring presentations by Dr. Jennifer Miller, from the University of Florida, and Dr. Theresa Strong, from the Foundation for Prader-Willi Research. Dr. Miller will discuss the current treatment landscape and unmet medical need for patients with Prader-Willi Syndrome (PWS), and data from Soleno's once-daily Diazoxide Choline
- Soleno Therapeutics to Present at the H.C. Wainwright Virtual BioConnect 2021 ConferenceREDWOOD CITY, Calif., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that management will present a corporate overview at the H.C. Wainwright Virtual BioConnect 2021 Conference, being held January 11-14, 2021. The presentation will be available on-demand beginning on Monday, January 11, 2021, in the Investors section on the Company’s website at www.soleno.life. About Soleno Therapeutics, Inc.Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company’s lead